Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nuodikang Weiguang, officially Beijing Nuodikang Weiguang Pharmaceutical Technology Co., Ltd., is a key research and development subsidiary of Tibet Rhodiola Pharmaceutical Holding (Tibet Nuodikang). The company focuses on the development and technical refinement of pharmaceuticals for cardiovascular and cerebrovascular diseases, integrating traditional Tibetan medicine insights with modern biotechnology. It is primarily responsible for the R&D and regulatory maintenance of major products like Xinhuo (Recombinant Human Brain Natriuretic Peptide), a significant therapy for acute heart failure in the Chinese market. Based in Beijing, Nuodikang Weiguang serves as the strategic innovation hub for its parent company's biopharmaceutical and natural product portfolio.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nuodikang Weiguang.